ALIGOS THERAPEUTICS, INC.

(ALGS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Catching Up With Late Market Declines

01/26/2022 | 04:02pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALIGOS THERAPEUTICS, INC. 3.48% 1.19 Delayed Quote.-89.97%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) -0.08% 0.7083 Delayed Quote.-2.18%
BRITISH POUND / US DOLLAR (GBP/USD) 0.00% 1.25856 Delayed Quote.-7.30%
CANADIAN DOLLAR / US DOLLAR (CAD/USD) -0.13% 0.7789 Delayed Quote.-1.41%
EURO / US DOLLAR (EUR/USD) 0.10% 1.0696 Delayed Quote.-5.60%
HEPION PHARMACEUTICALS, INC. 1.93% 0.7114 Delayed Quote.-37.60%
IMMUNOCORE HOLDINGS PLC -2.78% 28.71 Delayed Quote.-16.15%
INDIAN RUPEE / US DOLLAR (INR/USD) 0.02% 0.012903 Delayed Quote.-3.88%
NASDAQ COMP. 1.51% 11434.74 Real-time Quote.-28.00%
NEW ZEALAND DOLLAR / US DOLLAR (NZD/USD) -0.09% 0.647 Delayed Quote.-5.70%
TYME TECHNOLOGIES, INC. -3.92% 0.2329 Delayed Quote.-61.38%
All news about ALIGOS THERAPEUTICS, INC.
05/23Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
GL
05/23Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
GL
05/17Top Premarket Gainers
MT
05/05SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to..
MT
05/04Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q1 Loss $-0.84, vs. Street Est of $-0.7..
MT
05/04ALIGOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/04Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/04Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial R..
GL
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
GL
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
AQ
More news
Analyst Recommendations on ALIGOS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 2,58 M - -
Net income 2022 -118 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,45x
Yield 2022 -
Capitalization 50,8 M 50,8 M -
Capi. / Sales 2022 19,7x
Capi. / Sales 2023 -
Nbr of Employees 95
Free-Float 77,2%
Chart ALIGOS THERAPEUTICS, INC.
Duration : Period :
Aligos Therapeutics, Inc. Technical Analysis Chart | ALGS | US01626L1052 | MarketScreener
Technical analysis trends ALIGOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,19 $
Average target price 4,70 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Lawrence M. Blatt Chairman & Chief Executive Officer
Leonid N. Beigelman President & Director
Lesley Ann Calhoun Chief Financial Officer & Executive Vice President
Julian A. Symons Chief Scientific Officer & Executive VP
John Fry Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ALIGOS THERAPEUTICS, INC.-89.97%49
MODERNA, INC.-48.48%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-27.93%38 232
SEAGEN INC.-11.73%24 569
ICON PUBLIC LIMITED COMPANY-31.56%17 581